Minimal Benefit for Decision Aid About Prolonged Ventilation

Share this content:
Minimal Benefit for Decision Aid About Prolonged Ventilation
Minimal Benefit for Decision Aid About Prolonged Ventilation

FRIDAY, Feb. 1, 2019 (HealthDay News) -- A personalized web-based decision aid about prolonged mechanical ventilation does not improve prognostic concordance between clinicians and surrogate decision makers, according to a study published online Jan. 29 in the Annals of Internal Medicine.

Christopher E. Cox, M.D., from Duke University in Durham, North Carolina, and colleagues examined whether a decision aid relating to prolonged mechanical ventilation, compared with usual care, improved concordance for one-year survival estimates between surrogate decision makers and clinicians in a multicenter randomized trial. Participants included 277 adult patients receiving prolonged mechanical ventilation, 416 surrogates, and 427 intensive care unit (ICU) clinicians. The personalized decision aid provided prognostic estimates, explained treatment options, and interactively clarified patient values. The control group received information according to usual care practices.

The researchers observed no difference in concordance improvement between the intervention and control groups (mean difference in score change from baseline, −1.7 percentage points; P = 0.6). The intervention and control groups did not differ in terms of surrogates' postintervention estimates of patients' one-year prognoses (mean, 86 versus 92.5 percent; P = 0.23); these estimates were more optimistic than the results of a validated prediction model and physicians' estimates (median, 56 and 50 percent, respectively). Forty-three percent of intervention surrogates favored a more aggressive treatment option than reported patient preference. Compared with control surrogates, intervention surrogates had greater reduction in decisional conflict (mean difference in change from baseline, 0.4 points; P = 0.041).

"Future approaches to decision support in ICU settings will likely require greater individualized attention for both the cognitive and affective challenges of decision making," the authors write.

One author disclosed financial ties to Biomarck Pharmaceuticals.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA: Gout Drug Uloric Increases Risk of Death

FDA: Gout Drug Uloric Increases Risk of Death

Medication is associated with increased risk of heart-related death and death from all causes

Since Early 2000s, Overdose Death Rates Are Highest in U.S.

Since Early 2000s, Overdose Death Rates Are Highest ...

U.S. was not an outlier in terms of drug overdose mortality prior to the early 2000s

National Health Spending Set to Increase 5.5 Percent Annually

National Health Spending Set to Increase 5.5 Percent ...

Long-observed demographic and economic factors expected to drive growth in health spending

is free, fast, and customized just for you!




Already a member?

Sign In Now »